Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cancer immunotherapy: the interferon-alpha experience.

John Kirkwood1

  • 1University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213-2582, USA.

Seminars in Oncology
|June 18, 2002
PubMed
Summary

Interferon-alfa (IFN-alpha) shows promise for treating cancers and viral infections, but its effectiveness varies. Combining IFN-alpha with other treatments may enhance therapeutic potential, though side effects remain a challenge.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

On thresholds for controlling negative particle (PM<sub>2.5</sub>) readings in air quality reporting.

Environmental monitoring and assessment·2023
Same author

Urinary nitrate concentration as a marker for kidney transplant rejection.

BMC nephrology·2020
Same author

Low-cost sensors as an alternative for long-term air quality monitoring.

Environmental research·2020
Same author

[Neratinib + Valproate] exposure permanently reduces ERBB1 and RAS expression in 4T1 mammary tumors and enhances M1 macrophage infiltration.

Oncotarget·2018
Same author

Unconventional Approaches to Modulating the Immunogenicity of Tumor Cells.

Advances in cancer research·2018
Same author

The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib.

Cancer biology & therapy·2017

Area of Science:

  • Immunology
  • Oncology
  • Virology

Background:

  • Interferons (IFNs) possess antiviral, antiproliferative, and immunomodulatory functions.
  • Interferon-alfa (IFN-alpha) is approved for treating hairy cell leukemia, AIDS-related Kaposi's sarcoma, and condylomata acuminata.
  • IFN-alpha exhibits distinct antitumor and antiviral efficacies.

Purpose of the Study:

  • To explore the therapeutic potential of Interferon-alfa (IFN-alpha).
  • To investigate the efficacy of IFN-alpha in combination therapies.
  • To identify optimal strategies for utilizing IFN-alpha in clinical practice.

Main Methods:

  • Review of existing clinical data and trials involving IFN-alpha.
  • Analysis of combination therapy outcomes (e.g., IFN-alpha with 5-fluorouracil or zidovudine).
  • Assessment of treatment limitations, including side effects like flu-like syndrome.

Main Results:

  • IFN-alpha demonstrates efficacy as a single agent in specific conditions.
  • Combination therapies (IFN-alpha + 5-fluorouracil for colorectal carcinoma; IFN-alpha + zidovudine for acquired immune deficiency disorder) show enhanced efficacy.
  • Flu-like syndrome is a significant limiting factor for IFN-alpha's clinical application.

Conclusions:

  • IFN-alpha is a moderately effective therapeutic agent for certain diseases.
  • The greatest therapeutic potential of IFNs may be realized in combination therapies.
  • Further research is needed to elucidate mechanisms, optimize combinations, and establish appropriate preclinical models for rational IFN-alpha use.

Related Experiment Videos